Pharmaceutical Attorneys Dangerous Drugs Defective Medical Devices Medical Conditions Currently Accepted Cases Our Lawyers Do I Have a Case? Contact Us

Pfizer Settles Pristiq Lawsuit for $67 Million

Drug manufacturing giant Pfizer Inc has settled a class-action lawsuit with shareholders who were misled about risks associated with the antidepressant Pristiq. The cost to Pfizer will be a whopping $67.5 million.

The all-cash settlement was made public on November 9, one month after Pfizer settled a different lawsuit accusing the company of misleading investors about clinical trial results for the arthritis drug Celebrex; that settlement totaled $164 million.

The Pristiq lawsuit revolves around a large drop in the stock value of Wyeth shares (the company was acquired by Pfizer in 2009) that occurred on July 24, 2007. The drop, which caused a loss of over $7 billion of share value, was a result of the Food and Drug Administration’s refusal to approve Pristiq to treat "hot flashes" in post-menopausal women because of potential heart and liver problems associated with the drug.

Shareholders claim that Wyeth concealed these adverse side effects, knowingly allowing stock prices to be inflated between June 26, 2006 and July 24, 2007.

The settlement comes after almost six months of mediation. It is awaiting approval by U.S. District Judge Richard Sullivan in Manhattan.

Categories: Dangerous Drugs

Comments

No Comments Posted
Mixup at GlaxoSmithKline Plants Leads to Recalls
GlaxoSmithKline, the manufacturer of Avandia, recently issued a recall of near 400k bottles of their high blood pressure medication for fear of a poss... Read More [+]
FDA Approves Second Weight Loss Drug
The Food and Drug Administration (FDA) approved Vivus Inc.'s weight loss drug Qysmia on July 17, the second anti-obesity pill given the FDA nod of... Read More [+]
Studies Suggest Lexapro Link to Congenital Heart Defects
Lexapro is a drug prescribed as an antidepressant or "SSRI" (selective serotonin reuptake inhibitor). It has recently become the subject of ... Read More [+]